The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Uptake of second-line anticancer therapy after first-line pembrolizumab in patients with stage IV non–small cell lung cancer with PD-L1 > 50%: Comparison between clinical trials and the real world.
 
Rebekah Rittberg
Research Funding - AstraZeneca
 
Lauren Jones
No Relationships to Disclose
 
Bonnie Leung
No Relationships to Disclose
 
Aria Shokoohi
No Relationships to Disclose
 
D N Ionescu
No Relationships to Disclose
 
Alexandra Pender
No Relationships to Disclose
 
Ren Yuan
No Relationships to Disclose
 
Selina K. Wong
No Relationships to Disclose
 
Zamzam Salam Al-Hashami
No Relationships to Disclose
 
Ying Wang
Honoraria - AstraZeneca Canada; Merck; Takeda
Research Funding - AstraZeneca (Inst); Roche (Inst)
 
Cheryl Ho
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Merck; Novartis Canada Pharmaceuticals Inc; Pfizer; Roche; Takeda
Research Funding - AstraZeneca (Inst); EMD Serono (Inst); Roche Canada (Inst)